Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 634.00
Bid: 634.00
Ask: 635.00
Change: 1.00 (0.16%)
Spread: 1.00 (0.158%)
Open: 644.00
High: 644.00
Low: 630.00
Prev. Close: 633.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

19 May 2022 17:00

RNS Number : 1662M
Tate & Lyle PLC
19 May 2022
 

Tate & Lyle PLC

 

Notification of transactions by Persons Discharging Managerial Responsibilities

 

Tate & Lyle PLC (the 'Company') has been informed that on 18 May 2022 the following transactions occurred by Persons Discharging Managerial Responsibilities ('PDMR'), in respect of their interest in ordinary shares of 29 1/6 pence each in the capital of the Company ('Shares') under the Dividend Reinvestment Plan ('DRIP').

 

PDMR

Number of shares acquired under the DRIP

William Magee

1,844.464884

Andrew Taylor

21,483.522802

 

The notifications below, which have been made in accordance with the requirements of the UK Market Abuse Regulation, provide further detail.

 

Claire-Marie O'Grady

Company Secretary

19 May 2022

 

 

Notification and public disclosure of transaction by person discharging managerial responsibilities

 

Details of PDMR / person closely associated with them ("PCA")

a)

Name

William Magee

2.

Reason for the notification

a)

Position / status

President, Food & Beverage Solutions, North America

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tate & Lyle PLC

b)

LEI

2138008K14474WPKZ244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 29 1/6 pence each in the capital of Tate & Lyle PLC

 

GB00BP92CJ43

b)

Nature of the transaction

Acquisition of shares under the Tate & Lyle PLC Dividend Reinvestment Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£7.843142

1,844.464884

d)

Aggregated information

- Aggregated volume

- Price

 

 

1,844.464884

 

£14,466.40 GBP

e)

Date of the transaction

2022-05-18

f)

Place of the transaction

London Stock ExchangeXLON

 

 

 

Notification and public disclosure of transaction by person discharging managerial responsibilities

 

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Andrew Taylor

2.

Reason for the notification

a)

Position / status

President, Asia, Middle East, Africa and Latin America

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tate & Lyle PLC

b)

LEI

2138008K14474WPKZ244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 29 1/6 pence each in the capital of Tate & Lyle PLC

 

GB00BP92CJ43

b)

Nature of the transaction

Acquisition of shares under the Tate & Lyle PLC Dividend Reinvestment Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£7.843142

21483.522802

d)

Aggregated information

- Aggregated volume

- Price

 

 

21483.522802

 

£168,498.32 GBP

e)

Date of the transaction

2022-05-18

f)

Place of the transaction

London Stock ExchangeXLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUKVVRUUUVAAR
Date   Source Headline
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.